Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance
... 275.0 40% 720.6 522.1 38%
251.3 279.8 (10)% 508.2 ...rable impact of foreign exchange rates.
sales were $251.3 million in the second quarter of...
Drug May Extend Life When Breast Cancer Spreads
...delines from the American Society of Clinical Oncology stating that women at a heightened risk of developing breast cancer might benefit from the drug evista
(raloxifene) in addition to tamoxifen. Previous guidelines recommended only tamoxifen.
The U.S. National Cancer Institute h...
Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
...ntinues to Defend Intellectual Property Rights for evista
INDIANAPOLIS, April 22 /PRNewswire-FirstCall/...ring that the intellectual property protection for evista
remains in place until the Court renders its final...or Lilly. "We believe Teva's challenges to Lilly's evista
patents are without merit and we expect to prevail...
Lilly Reports Strong First-Quarter 2009 Results
...ently prohibits the launch of a generic version of evista
by Teva Pharmaceuticals. The company expects a rul... 335.3 247.2 36%
256.9 261.1 (2...favorable impact of foreign exchange rates.
Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene
...or Lilly. "We believe Teva's challenges to Lilly's evista
patent are without merit and we expect to prevail ... our patents against those who violate them."
is a breakthrough medicine indicated for the treat... Teva Pharmaceuticals Industries Ltd.
EVISTA(R), a selective estrogen receptor modulat...
Lilly Reports Fourth-Quarter and Full-Year 2008 Results
... 244.1 31% 1,154.7 854.0 35%
269.0 285.8 (6)% 1,075.6 ...avorable impact of
foreign exchange rates.
sales were $269.0 million in the fourth quarter of...
Lilly Caps Successful Year with Strong Fourth-Quarter Results
sales are reported in Lilly's revenue.
sales were $285.8 million in the fourth quarter, a...wer
For the full year of 2007, worldwide evista
sales increased 4 percent,
to $1.091 billion. U.S. evista
sales for 2007 were $706.1 million, a 6
Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy
...r review in the U.S. and
European Union for a new indication for glucocorticoid induced
osteoporosis, or GIOP.
The FDA recently approved evista
for a new use to reduce the risk of
invasive breast cancer in two populations: postmenopausal women with
osteoporosis and postmenopausal women at high...
Lilly Delivers Strong Third-Quarter Results
...er, the U.S. Food and Drug Administration approved evista
for a new use to reduce the risk of invasive b...change rates, offset in part by declining
prices. evista evista
sales were $263.2 million in the third quarter, a ...
FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
... Manufacturer calls evista
a valuable tool, but critics say its heart risks o...and Company said Friday that its osteoporosis drug evista
has received U.S. approval for use in preventing b... Committee voted 8 to 6 to recommended approval of evista
(raloxifene) for postmenopausal women with osteopo...
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
...nsulin program and its recombinant human hyaluronidase enzyme
technology. Prior to leading Lilly's inhaled insulin program, Dr. Muchmore
served on the evista
Product Team for osteoporosis and breast cancer
indications from 1995 to 1999 and as its Physician Group Leader from 1997
to 1999. He is the recipient...
Lilly Reports Solid Second-Quarter Results
...ide the U.S. increased 28
percent, to $233.8 million, driven primarily by higher demand and the
favorable impact of foreign exchange rates.
sales were $279.8 million in the second quarter of 2008, a 1
percent increase compared with the second quarter of 2007. U.S. sales of
CBI and PharmaVoice Announce Recipients of the Strategic Patient Adherence Awards
...d Robert Nauman, BioPharma Advisors and a judge for the
SPA awards. Rx Canada and their client (Eli Lilly Canada) received an
innovation award for the evista
Inner Strength Program which ensured that
pharmacists followed up with patients 2 weeks after their first
intervention. Finally, AstraZeneca received ...
Lilly Reports Solid First-Quarter Results
...es, net of expenses, was
reported in Lilly's other income. After the acquisition of ICOS, all Cialis
sales are reported in Lilly's revenue.
sales were $261.1 million in the first quarter of 2008, a 1
percent decrease compared with the first quarter of 2007. U.S. sales of
Evista were essent...